CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \[IHC\] 3+/2+/1+) advanced high-grade epithelial ovarian...
Phase 3
Berlin, Germany and 231 other locations
followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...
Phase 3
Berlin, Germany and 213 other locations
of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...
Phase 3
Berlin, Germany and 126 other locations
of Estrogen-receptor (ER) positive high and low grade epithelial ovarian cancer (including fallopian tube and primary peritoneal ca...
Phase 3
Berlin, Germany and 53 other locations
choice of chemotherapy in subjects with platinum-resistant ovarian cancer whose tumors are positive for cyclin E1 protein expressio...
Phase 3
Berlin, Germany and 58 other locations
study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already ...
Phase 3
Berlin, Germany and 176 other locations
to chemotherapy and in maintenance, in patients with low grade ovarian cancer (including patients with primary peritoneal and / or...
Phase 2
Berlin, Germany and 1 other location
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (I...
Phase 3
Berlin, Germany and 104 other locations
(PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, expressing hig...
Phase 3
Berlin, Germany and 298 other locations
This is a multi-center, prospective, open-label, phase II trial. Patients with suspected advanced ovarian cancer planned to undergo...
Phase 2
Berlin, Germany and 5 other locations
Clinical trials
Research sites
Resources
Legal